This study is looking at how the timing of giving a medicine called ketamine affects stopping seizures in adults with refractory status epilepticus (RSE). RSE is a type of seizure that doesn't stop with usual treatments. You could be eligible if you are 18 or older and have RSE that hasn't responded to at least two other seizure medicines. The study will compare giving ketamine early along with midazolam, another seizure medicine, versus giving midazolam first and then ketamine later. The main goal is to see how quickly seizures stop with these different approaches. The study is currently unclear about its recruitment status and plans to enroll 50 participants.

Study design

This is an interventional study that will randomly assign participants to one of two groups: early ketamine plus midazolam, or midazolam followed by late ketamine. It is a pilot feasibility study.

What's involved

Participants will receive continuous video EEG monitoring, and medication doses will be adjusted every 20 minutes if seizures continue. The study will also collect information on your hospital stay and recovery.

Compensation

Not stated in the trial record.

Follow-up

Your functional outcomes will be assessed at discharge, 3 months, and 6 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.